Spring Valley Acquisition Corp. II - Rights Stock (NASDAQ: SVIIR)

Latest News for Spring Valley Acquisition Corp. II - Rights Stock (NASDAQ:SVIIR)

Spring Valley Acquisition Corp. II - Rights

<p>Telsey Advisory Group  analyst Cristina Fernandez   maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Market Perform and maintains $8 price target.</p>


News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Under Armour, Maintains $8 Price Target

WIIM

GWAV

Greenwave Technology Solutions shares are trading higher amid abnormally-high volume. The stock has seen interest from retail investors on social media.

<p>Shares of marijuana growers and cannabis-related companies are trading higher Thursday after<strong> President Biden</strong> announced that the Department of Justice has moved to reclassify marijuana from a <a href="https://www.benzinga.com/markets/cannabis/24/05/38880719/biden-announces-monumental-marijuana-rescheduling-doj-to-take-next-steps">Schedule I substance to a Schedule III. </a></p>
<p><strong>The Details:</strong></p>
<p>The White House announcement comes several weeks after the Department of Justice confirmed the DEA was moving to reclassify cannabis as a Schedule III drug.</p>
<p>President Biden <a href="https://twitter.com/POTUS/status/1791152464617431389">posted </a>a video on the social media platform <strong>X</strong> with the following caption:&nbsp;</p>
<p>"Too many lives have been upended because of our failed approach to marijuana. So today, the @TheJusticeDept is taking the next step to reclassify marijuana from a Schedule I to a Schedule III drug under federal law."</p>
<p>Major players in the marijuana industry, including <strong>Canopy Growth Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>),<strong> Aurora Cannabis Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>)<strong> </strong>and <strong>Tilray Brands, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), shares are moving on the long-awaited news.&nbsp;</p>
<p>Smaller marijuana-growers, including <strong>IM Cannabis Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>), and ancillary pot-plays, like <strong>Leafly Holdings, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>), are also climbing on the news.&nbsp;</p>
<p>Cannabis ETFs, including the <strong>AdvisorShares Trust AdvisorShares Pure US Cannabis ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) and the <strong>Amplify ETF Trust Amplify Alternative Harvest ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MJ#NYSE">MJ</a>), </strong>offer broad exposure to the cannabis industry and are are also up following President Biden's reclassification announcement.&nbsp;</p>
<p><em>Related News: </em><strong><a href="https://www.benzinga.com/markets/cannabis/24/05/38880719/biden-announces-monumental-marijuana-rescheduling-doj-to-take-next-steps">Biden Announces &#8216;Monumental&#8217; Marijuana Rescheduling, DOJ To Take Next Steps</a></strong></p>
<p><strong>CGC, ACB, TLRY, IMCC Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Canopy Growth shares are up 15.7% at $11.47, Aurora Cannabis shares are up 11.4% at $7.93, Tilray shares are up 6.28% at $2.20 and IM Cannabis shares are up 10% at 78 cents at the time of publication Thursday.</p>
<p><em>Image: asdqwejkl from Pixabay</em></p>


Cannabis

Movers

IMCC

LFLY

MSOS

TLRY

Weed Stocks Rally After Biden Makes Marijuana Reclassification Announcement

<p>High-rolling investors have positioned themselves bearish on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GEV often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for GE Vernova. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 27% bullish and 54% bearish. Among all the options we identified, there was one put, amounting to $27,280, and 10 calls, totaling $732,007.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $165.0 and $175.0 for GE Vernova, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for GE Vernova's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GE Vernova's whale activity within a strike price range from $165.0 to $175.0 in the last 30 days. </p>
<h3>GE Vernova Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882684_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.9</td>
<td>$175.00</td>
<td>$153.0K</td>
<td>2.7K</td>
<td>604</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$9.4</td>
<td>$9.1</td>
<td>$9.1</td>
<td>$175.00</td>
<td>$91.0K</td>
<td>2.7K</td>
<td>432</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$9.6</td>
<td>$9.3</td>
<td>$9.6</td>
<td>$175.00</td>
<td>$86.4K</td>
<td>2.7K</td>
<td>92</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$9.0</td>
<td>$8.2</td>
<td>$8.5</td>
<td>$175.00</td>
<td>$85.0K</td>
<td>2.7K</td>
<td>1.5K</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$8.8</td>
<td>$8.2</td>
<td>$8.48</td>
<td>$175.00</td>
<td>$84.8K</td>
<td>2.7K</td>
<td>1.4K</td>
</tr>
</tbody>
</table>
</p>
<h3>About GE Vernova</h3>
<p>GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.</p>
<p>In light of the recent options history for GE Vernova, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of GE Vernova</h3>
<ul>
<li>With a volume of 845,426, the price of GEV is down -0.05% at $167.78. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<h3>What The Experts Say On GE Vernova</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $164.2.</p>
<ul>
<li>In a cautious move, an analyst from Evercore ISI Group downgraded its rating to Outperform, setting a price target of $174. </li>
<li>Reflecting concerns, an analyst from Raymond James lowers its rating to Outperform with a new price target of $160.</li>
<li>Reflecting concerns, an analyst from Exane BNP Paribas lowers its rating to Outperform with a new price target of $177.</li>
<li>An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $150. </li>
<li>An analyst from B of A Securities has decided to maintain their Neutral rating on GE Vernova, which currently sits at a price target of $160. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for GE Vernova with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

This Is What Whales Are Betting On GE Vernova

<p>Deep-pocketed investors have adopted a bullish approach towards Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAVA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Cava Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 37% bearish. Among these notable options, 2 are puts, totaling $74,750, and 6 are calls, amounting to $776,573.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $80.0 for Cava Group over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Cava Group options trades today is 183.5 with a total volume of 2,131.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Cava Group's big money trades within a strike price range of $50.0 to $80.0 over the last 30 days.</p>
<h3>Cava Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882679_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$32.0</td>
<td>$31.5</td>
<td>$31.5</td>
<td>$50.00</td>
<td>$157.5K</td>
<td style="text-align: right;">39</td>
<td style="text-align: right;">350</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$31.5</td>
<td>$30.8</td>
<td>$31.5</td>
<td>$50.00</td>
<td>$157.5K</td>
<td style="text-align: right;">39</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$31.5</td>
<td>$31.5</td>
<td>$31.5</td>
<td>$50.00</td>
<td>$157.5K</td>
<td style="text-align: right;">39</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$31.1</td>
<td>$30.5</td>
<td>$30.8</td>
<td>$50.00</td>
<td>$154.1K</td>
<td style="text-align: right;">39</td>
<td style="text-align: right;">600</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/31/24</td>
<td>$4.4</td>
<td>$4.3</td>
<td>$4.3</td>
<td>$80.00</td>
<td>$115.5K</td>
<td style="text-align: right;">334</td>
<td style="text-align: right;">815</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cava Group</h3>
<p>Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.</p>
<p>Following our analysis of the options activities associated with Cava Group, we pivot to a closer look at the company's own performance.</p>
<h3>Cava Group's Current Market Status</h3>
<ul>
<li>With a volume of 748,956, the price of CAVA is down -0.55% at $78.2. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cava Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


CAVA

Cava Group Unusual Options Activity For May 16

<p>High-rolling investors have positioned themselves bearish on Canopy Gwth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CGC often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 15 options trades for Canopy Gwth. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 33% bullish and 60% bearish. Among all the options we identified, there was one put, amounting to $31,800, and 14 calls, totaling $802,572.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $8.5 to $12.0 for Canopy Gwth during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Canopy Gwth options trades today is 4314.56 with a total volume of 68,596.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Canopy Gwth's big money trades within a strike price range of $8.5 to $12.0 over the last 30 days.</p>
<h3>Canopy Gwth Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882674_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CGC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/24/24</td>
<td>$1.03</td>
<td>$1.03</td>
<td>$1.03</td>
<td>$10.50</td>
<td>$203.5K</td>
<td>319</td>
<td>3.2K</td>
</tr>
<tr>
<td>CGC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$1.85</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$10.00</td>
<td>$94.3K</td>
<td>8.9K</td>
<td>10.7K</td>
</tr>
<tr>
<td>CGC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$2.39</td>
<td>$2.29</td>
<td>$2.39</td>
<td>$9.00</td>
<td>$81.2K</td>
<td>4.2K</td>
<td>1.6K</td>
</tr>
<tr>
<td>CGC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/31/24</td>
<td>$2.13</td>
<td>$1.59</td>
<td>$1.84</td>
<td>$8.50</td>
<td>$58.5K</td>
<td>214</td>
<td>1.7K</td>
</tr>
<tr>
<td>CGC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$1.03</td>
<td>$1.03</td>
<td>$1.03</td>
<td>$11.00</td>
<td>$48.5K</td>
<td>3.2K</td>
<td>796</td>
</tr>
</tbody>
</table>
</p>
<h3>About Canopy Gwth</h3>
<p>Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz &amp; Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.</p>
<h3>Present Market Standing of Canopy Gwth</h3>
<ul>
<li>Currently trading with a volume of 22,253,498, the CGC's price is up by 15.49%, now at $11.45. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Canopy Gwth, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Canopy Gwth's Options: A Look at What the Big Money is Thinking

<p>President <strong>Joe Biden</strong> announced on Thursday that his administration is officially moving <a href="https://www.benzinga.com/cannabis">to reschedule marijuana</a> under federal law, while praising what he called a &#8220;monumental&#8221; step.</p>
<p>"Today my administration took a major step to reclassify marijuana from a schedule one drug to a schedule three drug. It's an important move toward reversing long-standing inequities. Today's announcement builds on the work we've already done, and it adds to the action we've taken to lift barriers to housing, employment, small business loans and so much more for tens of thousands of Americans," Biden said.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Too many lives have been upended because of our failed approach to marijuana.<br /><br />So today, the <a href="https://twitter.com/TheJusticeDept?ref_src=twsrc%5Etfw">@TheJusticeDept</a> is taking the next step to reclassify marijuana from a Schedule I to a Schedule III drug under federal law.<br /><br />Here&#39;s what that means: <a href="https://t.co/TMztSyyFYm">pic.twitter.com/TMztSyyFYm</a></p>
<p>&mdash; President Biden (@POTUS) <a href="https://twitter.com/POTUS/status/1791152464617431389?ref_src=twsrc%5Etfw">May 16, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<h2 class="wp-block-heading">Justice Dept. On The Move</h2>
<p>The Justice Department is expected to post its proposed rules to move cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA) in the Federal Register, a senior administration official said on Thursday. A 60-day public comment period will follow.</p>
<p>"Look folks, no one should be in jail for merely using or possessing marijuana. Period," the president said. "Far too many lives have been upended because of a failed approach to marijuana and I'm committed to righting those wrongs. You have my word on it."</p>
<p>The White House announcement comes several weeks after the Department of Justice confirmed the <a href="https://www.benzinga.com/markets/cannabis/24/04/38530190/breaking-dea-reportedly-moves-to-reschedule-cannabis-stocks-rise-sharply-on-the-news">DEA was moving to reclassify cannabis</a> as a Schedule III drug.</p>
<h2 class="wp-block-heading">Cannabis Stocks Rose On The News</h2>
<p>Following the historic announcement, cannabis stocks quickly reacted with<strong>&nbsp;AdvisorShares Pure US Cannabis ETF</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) trading up 7.54% at $10.34 per share at the time of writing. Another marijuana ETF,&nbsp;<strong>AdvisorShares Pure Cannabis</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>), was up 5.41% at $4.4 per share.</p>
<p>Popular weed giants,&nbsp;<strong>Canopy Growth&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>)<strong>&nbsp;Aurora Cannabi</strong>s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) were trading 15.35% higher at $11.43 per share and 11.10% at $7.91 per share, respectfully.</p>
<p><strong>Curaleaf Holdings</strong>&nbsp;(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>) was slightly up, trading 5.98% higher at $5.95 per share, and one of the biggest cannabis players in Canada and the US,&nbsp;<strong>Tilray</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) was trading just a bit higher or $6.75% with $2.21 per share.</p>
<p><em>The 19th Benzinga Cannabis Capital Conference, returns to Chicago this Oct. 8-9.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a>&nbsp;before prices surge by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.</em></p>
<p><em>Now Read: <a href="https://www.benzinga.com/markets/cannabis/24/05/38878750/mike-tysons-cannabis-products-available-in-even-more-dispensaries-in-colorado-via-new-partnershi">Mike Tyson&#8217;s Cannabis Products Available In &#8216;Even More Dispensaries&#8217; In Colorado Via New Partnership, Here&#8217;s Where To Find Them</a></em></p>
<p><em>Image created using artificial intelligence via Midjourney and Shutterstock photo.</em></p>


Politics

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

YOLO

Biden Announces 'Monumental' Marijuana Rescheduling, DOJ To Take Next Steps

<p>Ratings for Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Praxis Precision Medicine, presenting an average target of $116.43, a high estimate of $150.00, and a low estimate of $105.00. This current average has increased by 3.49% from the previous average price target of $112.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882509_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Praxis Precision Medicine is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$117.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Kambiz Yazdi</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$128.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Praxis Precision Medicine. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Praxis Precision Medicine compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Praxis Precision Medicine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Praxis Precision Medicine's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRAX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Praxis Precision Medicine analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Praxis Precision Medicine's Background</h2>
<p>Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.</p>
<h3>Praxis Precision Medicine: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Praxis Precision Medicine faced challenges, resulting in a decline of approximately <strong>-36.9%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Praxis Precision Medicine's net margin excels beyond industry benchmarks, reaching <strong>-9177.03%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-26.43%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Praxis Precision Medicine's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-23.38%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Praxis Precision Medicine's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.01</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PRAX

Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) in the last three months.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Coupang, presenting an average target of $25.86, a high estimate of $32.00, and a low estimate of $21.00. This current average has increased by 19.89% from the previous average price target of $21.57. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882489_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Coupang by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jennifer Han</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>John Yu</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>John Yu</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Peter Milliken</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$18.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Coupang. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Coupang compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Coupang's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Coupang's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CPNG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Coupang analyst ratings.</strong></a></p>
<h2>All You Need to Know About Coupang</h2>
<p>Coupang Inc is an e-commerce company. It sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Developing Offerings. The company generates maximum revenue from the Product Commerce segment. Product Commerce includes core retail (owned inventory) and marketplace offerings (third-party merchants) and Rocket Fresh, fresh grocery offering, as well as advertising products associated with these offerings.</p>
<h3>Coupang: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Coupang showcased positive performance, achieving a revenue growth rate of <strong>22.63%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Coupang's net margin is impressive, surpassing industry averages. With a net margin of <strong>0.07%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Coupang's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>0.12%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Coupang's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.04%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.89</strong>, Coupang adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CPNG

The Analyst Landscape: 7 Takes On Coupang

<p>Ratings for Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Caribou Biosciences, presenting an average target of $21.5, a high estimate of $24.00, and a low estimate of $19.00. A decline of 6.52% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882482_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Caribou Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$19.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Caribou Biosciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Caribou Biosciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Caribou Biosciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Caribou Biosciences's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRBU/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Caribou Biosciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Caribou Biosciences</h2>
<p>Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.</p>
<h3>Caribou Biosciences's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Caribou Biosciences's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately <strong>-30.64%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Caribou Biosciences's net margin excels beyond industry benchmarks, reaching <strong>-1697.57%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-11.59%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Caribou Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-9.83%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.08</strong>, Caribou Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CRBU

Expert Ratings For Caribou Biosciences

<p>In the last three months, 6 analysts have published ratings on Starwood Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Starwood Prop Trust, presenting an average target of $21.58, a high estimate of $23.00, and a low estimate of $20.00. Observing a downward trend, the current average is 1.15% lower than the prior average price target of $21.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882433_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Starwood Prop Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Laws</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$23.00</td>
<td>$23.50</td>
</tr>
<tr>
<td>Sarah Barcomb</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$20.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Starwood Prop Trust. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Starwood Prop Trust compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Starwood Prop Trust's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Starwood Prop Trust's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STWD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Starwood Prop Trust analyst ratings.</strong></a></p>
<h2>Delving into Starwood Prop Trust's Background</h2>
<p>Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment and Investing and Servicing Segment. The company generates the majority of its revenue from the Real estate commercial and residential lending segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.</p>
<h3>Starwood Prop Trust: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Starwood Prop Trust showcased positive performance, achieving a revenue growth rate of <strong>88.48%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Starwood Prop Trust's net margin is impressive, surpassing industry averages. With a net margin of <strong>50.5%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Starwood Prop Trust's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.42%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.22%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Starwood Prop Trust's debt-to-equity ratio is below the industry average at <strong>1.44</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


STWD

A Closer Look at 6 Analyst Recommendations For Starwood Prop Trust

<p>Raymond James  analyst Steven Seedhouse   upgrades Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) from Outperform to Strong Buy and raises the price target from $115 to $116.</p>


Upgrades

VKTX

Raymond James Upgrades Viking Therapeutics to Strong Buy, Raises Price Target to $116

<p>Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.04%. Currently, Welltower has a market capitalization of $61.15 billion. </p>
<p><strong>Buying $1000 In WELL:</strong> If an investor had bought $1000 of WELL stock 15 years ago, it would be worth <strong>$13,331.13</strong> today based on a price of $102.28 for WELL at the time of writing.</p>
<h3>Welltower's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882425_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

WELL

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $13,000 Today

<p>In the latest quarter, 4 analysts provided ratings for Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $49.75, along with a high estimate of $60.00 and a low estimate of $19.00. Observing a 1558.33% increase, the current average has risen from the previous average price target of $3.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882421_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Precision BioSciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Adjusts</td>
<td>Buy</td>
<td>$60.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Precision BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Precision BioSciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Precision BioSciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Precision BioSciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DTIL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Precision BioSciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Precision BioSciences: A Closer Look</h2>
<p>Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.</p>
<h3>Key Indicators: Precision BioSciences's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Precision BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>100.27%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Precision BioSciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>48.84%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Precision BioSciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>30.63%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Precision BioSciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.99%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.83</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DTIL

Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)

<p>ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) has outperformed the market over the past 15 years by 14.36% on an annualized basis producing an average annual return of 26.99%. Currently, ASML Holding has a market capitalization of $365.66 billion. </p>
<p><strong>Buying $100 In ASML:</strong> If an investor had bought $100 of ASML stock 15 years ago, it would be worth <strong>$3,591.06</strong> today based on a price of $926.68 for ASML at the time of writing.</p>
<h3>ASML Holding's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882420_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ASML

$100 Invested In ASML Holding 15 Years Ago Would Be Worth This Much Today

<p>In the preceding three months, 6 analysts have released ratings for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Newmont, presenting an average target of $47.25, a high estimate of $54.00, and a low estimate of $43.50. Observing a downward trend, the current average is 4.87% lower than the prior average price target of $49.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715882411_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Newmont among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bob Brackett</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Jackie Przybylowski</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Greg Barnes</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Greg Barnes</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Alexander Hacking</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$43.50</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Newmont. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Newmont compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Newmont's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Newmont's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NEM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Newmont analyst ratings.</strong></a></p>
<h2>Delving into Newmont's Background</h2>
<p>Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 6.9 million ounces of gold in 2024. However, after buying Newcrest, Newmont is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at end December 2023.</p>
<h3>Newmont's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Newmont's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>50.17%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Newmont's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.23%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Newmont's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.59%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Newmont's ROA excels beyond industry benchmarks, reaching <strong>0.31%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Newmont's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.33</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Newmont: 6 Analysts Share Their Views

<p>On the "Afford Anything" podcast, Suze Orman delivered a pointed critique on the notion of retiring early with a $2 million portfolio. She was direct in her advice, emphasizing the insufficiency of such an amount for early retirement. "Two million dollars is nothing," <a href="https://www.benzinga.com/personal-finance/24/02/37318402/you-are-going-to-burn-up-alive-suze-orman-hates-the-fire-movement-and-says-you-need-at-least-20-">Orman declared</a>, "It&#8217;s nothing. It&#8217;s pennies in today&#8217;s world, to tell you the truth."</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"><strong> How do you compare</strong></a>?</strong></li>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"><strong> </strong><strong>The percentage may shock you</strong></a>.</strong></li>
</ul>
<p>Orman expanded on the potential financial dangers that could deplete such savings quickly. "If you have $20 [million], $40 [million], $50 [million] or $100 million, be like me, okay. <a href="https://www.benzinga.com/personal-finance/24/04/38466698/are-you-saving-enough-to-be-in-the-top-3-of-retirees-heres-how-much-you-need">If you have that kind of money â€¦</a> and you want to retire, fine," she explained, contrasting this with the risks faced by those with less substantial sums. "But if you only have a few hundred thousand dollars, or a million, or $2 million, I&#8217;m here to tell you…if a catastrophe happens…what are you going to do? You are going to burn up alive."</p>
<p>Addressing the common retirement strategy of <a href="https://www.benzinga.com/personal-finance/24/05/38618728/suze-orman-calls-the-4-retirement-rule-very-dangerous-in-todays-challenging-economic-climate">withdrawing 4% annually</a>, Orman was skeptical: "I think that in the long run, $80,000, especially after taxes and as you get older, is not going to be enough. You may think it&#8217;s going to be enough, but it&#8217;s just not," she stated firmly.</p>
<p>Her advice underscores the importance of ample financial cushioning, particularly if unexpected costs arise, such as health care or family support needs. "Think about it logically," Orman urged, highlighting potential expenses that could easily top hundreds of thousands annually.&nbsp;</p>
<p><strong>Trending: Reddit user reveals his retirement account&#8217;s &#8220;hourly wage&#8221; —<a href="https://www.benzinga.com/money/retirement-hourly-wage"><strong> how much does your money really make per hour?</strong></a></strong></p>
<p>When asked if $3 million was enough Orman firmly stated it was not. "If you don&#8217;t have at least $5 million or $10 million, don&#8217;t retire early," Suze asserted.&nbsp;</p>
<p>Orman&#8217;s assertion that individuals need "at least $5 million to retire early" stirred a mix of reactions, with some viewing it as excessively cautious while others validate her perspective.&nbsp;</p>
<p>Financial Samurai supports Orman&#8217;s viewpoint, highlighting that with today&#8217;s low interest rates, a larger capital is necessary to generate sufficient risk-adjusted income for early retirement. This is particularly relevant considering the need to depend more on investment income due to the diminishing reliability of traditional retirement income sources like Social Security and pensions.</p>
<p>While Orman faced significant backlash for her statements, with critics arguing that her figures are unattainable for most, the underlying principle she advocates is prudence.&nbsp;</p>
<p>This idea resonates with a segment of the financial community that sees the wisdom in ensuring a substantial financial buffer to address uncertainties in retirement, especially given potential long-term trends such as increasing health care costs and ongoing economic fluctuations. Orman's conservative approach, advocating for a higher threshold of retirement savings, reflects a cautious strategy designed to safeguard against the unknowns of future decades.</p>
<p>Financial planning is crucial for a secure retirement, and while Suze Orman&#8217;s recommendations may not be suitable for everyone, <a href="https://www.benzinga.com/money/fam">consulting a financial advisor</a> can help you craft a personalized plan that aligns with your unique goals and risk tolerance. An advisor can help you assess your current financial situation, including your income, expenses, debts, and savings, and create a road map to reach your retirement goals.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Boomers and Gen Z agree they need a salary of around $125,000 a year to be happy,<a href="https://www.benzinga.com/money/genz-salary-adv"><strong> </strong><strong>but millennials say they need how much?</strong></a></strong></li>
<li><strong>Are you secretly doing better with your money than you think?<a href="https://www.benzinga.com/money/adv-financially-healthy"><strong> </strong><strong>Here are some signs you&#8217;re financially healthy.</strong></a></strong></li>
</ul>


Personal Finance

'$2 Million Is Nothing' Suze Orman Warns Don't Retire If You Don't Have At Least $5 Million Or $10 Million Saved

<p>Ladenburg Thalmann  analyst Jon Hickman   upgrades Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) from Neutral to Buy and maintains the price target from $2 to $2.</p>


WATT

Ladenburg Thalmann Upgrades Energous to Buy, Maintains Price Target to $2

<p><strong>Alibaba Group Holding Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) saw a rise in its shares Thursday afternoon after experiencing a decline on Tuesday following the release of its <a href="https://www.benzinga.com/pressreleases/24/05/b38810094/alibaba-group-announces-march-quarter-2024-and-fiscal-year-2024-results">quarterly earnings report.</a></p>
<p><strong>Here's What's Going On:</strong> In terms of earnings, Alibaba&#8217;s quarterly performance was mixed. While revenue figures surpassed expectations of $30.4 billion by 1.08%, coming in at $30.729 billion, the company reported lower-than-expected EPS of $1.40 compared to estimates of $1.41 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><strong>What&#8217;s New:</strong> Thursday&#8217;s positive movement may be partly due to an X <a href="https://twitter.com/CitronResearch/status/1791108355664085381">post</a> from Citron Research. The post expressed optimism about Alibaba&#8217;s future, highlighting its potential to emulate the successes of tech giants like <strong>Amazon</strong> and <strong>Microsoft</strong> in China. </p>
<p>&#8220;Alibaba ($BABA) gaining momentum should cruise past $100,&#8221; Citron Research said.</p>
<p>Specifically, the firm pointed to Alibaba&#8217;s AI cloud prospects and strategic investments as key factors driving its growth. The post&#8217;s positive sentiment appears to have resonated with investors, contributing to the uptick in Alibaba&#8217;s stock price Thursday.</p>
<p><strong>What Else:</strong> Barclays analyst<strong> Jiong Shao</strong> maintained an Overweight rating on Alibaba on Thursday, but lowered the price target from $109 to $107. Conversely, BofA Securities analyst <strong>Eddie Leung</strong> maintained a Buy rating on the stock and raised the price target from $99 to $103.</p>
<p>Overall, Thursday&#8217;s movement in Alibaba&#8217;s stock likely reflects a combination of factors, including the recent earnings report, a bullish tweet from Citron Research and analyst updates. Investors should continue to monitor Alibaba&#8217;s performance closely as it navigates challenges and opportunities in the Chinese market landscape.</p>
<p><em>See Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38819576/whats-going-on-with-tilray-stock-tuesday">What&#8217;s Going On With Tilray Stock Tuesday?</a></em></p>
<p><strong>BABA Price Action: </strong>Alibaba shares are currently up 6.88% at $86.56 at publication time, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-1024x533.png" alt="" class="wp-image-342045" style="width:538px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA.png 1203w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><em>Photo: zhu difeng from Shutterstock</em></p>


Global

BABA

Alibaba Shares Bounce Back Thursday: What's Going On?

<p>Bernstein  analyst Bob Brackett   maintains Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Market Perform and lowers the price target from $46 to $45.</p>
